Myoview at a Glance
- Rapid cardiac imaging
Myoview can begin to acquire diagnostic information in as soon as 15 minutes for stress MPI *1
Potential for shorter throughput and fewer repeat scans.2
Myoview demonstrated significantly shorter completion time for both rest studies and throughput time2
Patients receiving Myoview required fewer repeat scans due to interference of extra cardiac activity2- Flexible one- or two-day protocols
may help optimize department scheduling, as well as enable a through-put improved workflow
Kit reconstitution and image acquisition1
Supporting Materials
Customer Resources
Looking for medical information?
Invested in the advancement of Nuclear Cardiology—both today and tomorrow
- Myoview [prescribing information]. Arlington Heights, IL: GE Healthcare; 2017.
- Ravizzini GC, Hanson MW, Shaw LK, et al. Nucl Med Comm. 2002;23:203-208. Erratum in April 2006.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
- Risks Associated With Exercise or Pharmacologic Stress: Patients evaluated with
exercise or pharmacologic stress may experience serious adverse reactions such as
myocardial infarction, arrhythmia, hypotension, and bronchoconstriction, as well as
cerebrovascular reactions such as headache, paraesthesias, convulsions, somnolence, and
cerebrovascular accident, including hemorrhage. Perform stress testing in a setting where
cardiac resuscitation equipment and trained staff are readily available. When pharmacologic
stress is selected as an alternative to exercise, perform the procedure in accordance with the
pharmacologic stress agent's Prescribing Information
- Radiation Risks: Technetium Tc99m contributes to a patient’s overall long-term cumulative
radiation exposure. Long-term cumulative radiation exposure is associated with an increased
risk of cancer. Ensure safe handling and preparation radiolabeling procedures to protect
patients and healthcare workers from unintentional radiation exposure. Encourage adequate
hydration; instruct patients to void when the examination is completed and as often
thereafter as possible
- Hypersensitivity Reactions:
Hypersensitivity reactions, including anaphylaxis, dyspnea,
bronchospasm, throat tightness, coughing, tachycardia, chest pain, hypotension, abdominal
pain, and cutaneous reactions (rash, urticuria, pruritus, erythema, and swelling or
angiodema) have been observed after the administration of MYOVIEW. Always have
cardiopulmonary resuscitation equipment and personnel available, and monitor all patients
for hypersensitivity reactions
ADVERSE REACTIONS
- Serious episodes of angina, ventricular tachycardia, and respiratory arrest were reported.Other events included angina, hypertension, torsades de pointes, vomiting, abdominaldiscomfort, cutaneous allergy, hypotension, dyspnea, metallic taste, burning of the mouth,and smell alteration. The following were reported when used with pharmacological stress:Angina, flushing, dyspnea, headache, abdominal pain, dizziness, palpitations, nausea,hypotension, pain, cough, arrhythmia, bronchospasm, ECG (electrocardiogram) abnormalities,hypertension, vomiting, and asthenia. Postmarketing adverse reactions included rash,urticaria, abnormal vision, hypersensitivity reactions, and fever
USE IN SPECIFIC POPULATIONS
- Nursing Mothers: Technetium Tc99m tetrofosmin is present in human milk in small amounts (<1% of maternal dose). There are no data available regarding the effects of technetium Tc99m tetrofosmin on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for MYOVIEW and any other potential adverse effects on the breastfed child from MYOVIEW or from the underlying maternal condition. To decrease radiation exposure to the breastfed infant, advise a lactating woman to pump and discard for 60 hours (10 half-lives) after technetium Tc99m tetrofosmin administration.
- Pediatric Use: Safety and effectiveness in pediatric patients have not been established
- Geriatric Use: No overall differences in safety were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between elderly patients and younger patients, but greater sensitivity regarding some older individuals cannot be ruled out
- Prior to MYOVIEW administration, please read the full Prescribing Information for additional Important Safety Information.
- To report SUSPECTED ADVERSE REACTIONS, contact GE Healthcare at 800 654 0118 (option 2, then option 1) or the FDA at 800 FDA 1088 or www.fda.gov/medwatch.
PRODUCT INDICATIONS AND USE
MYOVIEWTM (Kit for the Preparation of Technetium Tc99m Tetrofosmin Injection) is indicated for myocardial perfusion imaging under rest and/or exercise or pharmacologic stress conditions to delineate regions of reversible myocardial ischemia or infarcted myocardium in patients with known or suspected coronary artery disease. MYOVIEW is also indicated for the assessment of left ventricular function (left ventricular ejection fraction and wall motion) in patients with known or suspected heart disease.